Anticancer Drug Toxicity in the Absence of Hypophyseal or Adrenal Secretion

  • P. Preziosi
  • P. Navarra
  • M. Vacca
Conference paper
Part of the Archives of Toxicology book series (TOXICOLOGY, volume 12)


Regimes of treatment with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or cyclophosphamide-adriamycin-5-fluorouracil(CAF) for breast cancer and 5-fluorouracil (5-FU) for prostate cancer may be used in patients with hormone-sensitive tumors after medical or surgical adrenalectomy or hypophy-sectomy (Craig-Henderson 1987). The anticancer drug hydroxyurea displayed a unique and marked toxicity in both pituitary- and adrenal-ablated animals (Vacca et al. 1985). The ability of intact, hypophysectomized, or adrenalectom-ized male adult rats to tolerate four anticancer drugs [busulfan (BU), carmustine (BCNU), cyclophosphamide (CY), and 5-FU] given according to the recommended treatment schedule and route in human cancer chemotherapy at doses corresponding to and 10–500 times greater than those employed per kilogram in humans (human therapeutic dose, Htd) (Salmon and Sartorelli 1987) was investigated. BU and BCNU are prescribed for neoplasm other than breast and prostate cancer but BU has caused “selective” pituitary insufficiency (Vivacqua et al. 1967) and BCNU may induce several hormonal changes due to pituitary stimulation (Kuo et al. 1975; Di Renzo et al. 1979).


Prostate Cancer Luteinizing Hormone Sudden Unexpected Death Pituitary Insufficiency Italian National Research Council 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Di Renzo GF, Schettini G, Annunziato L, Quattrone A, Preziosi P (1979) Modifiche di secrezioni endocrine indotte dalla somministrazione di farmaci antineoplastici. Giorn Ital Chemioter 26:255–261Google Scholar
  2. Craig-Henderson I, Hayes DF, Come ST, Harris JR, Canellos G (1987) New agents and new medical treatments for advanced breast cancer. Sem Oncol 14:34–64Google Scholar
  3. Kuo EYH, Esber JH, Taylor DJ, Bogden AE (1975) Effects of cancer chemotherapeutic agents on endocrine organs and serum levels of estrogens, progesterone, prolactin and luteinizing hormone. Cancer Res. 35:1975–1980PubMedGoogle Scholar
  4. Salmon SE, Sartorelli AC (1987) Cancer chemotherapy. In: Katzung BE (ed) Basic and clinical pharmacology, 3rd ed. Lange, Los Altos, pp 665–701Google Scholar
  5. Vacca M, De Gori N, del Carmine R, Navarra P, Preziosi P (1985) Replacement therapy against increased hydroxyurea toxicity in pituitary or adrenal ablated rats. Arch Toxicol Suppl 8:385–389PubMedCrossRefGoogle Scholar
  6. Vivacqua RJ, Haurant FJ, Ersley AJ (1967) “Selective” pituitary insufficiency secondary to busulphan. Ann Int Med 67:380–387PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • P. Preziosi
    • 1
  • P. Navarra
    • 1
  • M. Vacca
    • 2
  1. 1.Department of PharmacologyCatholic University of the Sacred HeartRomeItaly
  2. 2.Department of Pharmacology, Faculty of MedicineSassari UniversitySassariItaly

Personalised recommendations